Positive Data on Baxter's VIVIA HD System - Analyst Blog

a generic image of a graph
Credit: Shutterstock photo

Baxter International Inc. ( BAX ) recently presented clinical data supporting the safety and efficacy of its VIVIA Haemodialysis (HD) System, designed to deliver High Dose HD in the home environment. Following the release, shares of BAX, however, dropped by a marginal 0.1% to close at $73.64 yesterday.

BAX shared its VIVIA HD system data for the first time with the European nephrology community at the 51st Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), which took place from May 31 to Jun 3 in Amsterdam.


The VIVIA HD System is designed to support High Dose HD therapy - a more frequent and extended duration treatment administered in the form of short daily treatments or nocturnal treatments.

The VIVIA HD System's user-friendly features allow a greater number of haemodailysis patients to access High Dose HD therapy in their home environment. The system also includes a fully integrated wireless connectivity platform that allows physicians to comprehensively monitor home therapy remotely.

The VIVIA HD System received CE Mark approval for a European launch in Dec 2013. Year-to-date, the system is being introduced on a limited basis in select European dialysis clinics. BAX plans to expand the launch to other European countries in 2015.

VIVIA Clinical Studies

The first in-human study was a prospective, single arm clinical study conducted in haemodialysis centers in the U.S. Under the study, 22 patients received four HD treatments with the VIVIA HD system every week for 10 weeks.

In the second prospective, single arm clinical study carried out in haemodialysis centres in Canada, 17 patients received nocturnal HD treatments with the VIVIA HD system 3 times a week for 6 weeks.

Results from both the studies demonstrated the system's capability to accurately remove excess body fluid, as shown by a strong correlation established between fluid weights removed and weight change. The research further confirmed the system's ability to clear uremic toxins safely and reliably.

Other Prospects

Apart from its clinical advantages, additional data presented at the congress holds the VIVIA HD System as a potentially more sustainable and cost-effective therapy.

Results from another study established that the VIVIA HD System emitted the lowest amount of carbon compared to a currently-available home HD device and a conventional in-centre HD device that can be used for home dialysis. By means of a lower carbon footprint, the system is set to make a significant impact in delivering sustainable HD therapies.

Furthermore, other studies found High Dose HD at home to be cost effective when compared with conventional in-centre HD devices. Two separate analyses of High Dose HD in the U.K. confirmed that increased usage could lead to considerable cost savings and an increase in quality-adjusted, life-years gained.

Zacks Rank

Currently, BAX retains a Zacks Rank #3 (Hold). Some better-ranked medical product stocks worth considering are Cardica Inc. ( CRDC ), Eagle Pharmaceuticals Inc. ( EGRX ) and NeuroMetrix Inc. ( NURO ). All these stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BAXTER INTL (BAX): Free Stock Analysis Report

EAGLE PHARMACT (EGRX): Free Stock Analysis Report

NEUROMETRIX INC (NURO): Free Stock Analysis Report

CARDICA INC (CRDC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More